BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res 2019;25:6429-42. [PMID: 31439581 DOI: 10.1158/1078-0432.CCR-19-0836] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Chouhan S, Sawant M, Weimholt C, Luo J, Sprung RW, Terrado M, Mueller DM, Earp HS, Mahajan NP. TNK2/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability. Autophagy 2022;:1-26. [PMID: 35895804 DOI: 10.1080/15548627.2022.2103961] [Reference Citation Analysis]
2 Gallez B. The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. Front Pharmacol 2022;13:853568. [DOI: 10.3389/fphar.2022.853568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Arast Y, Heidary M, Tanbakousazan F, Behnamipour S, Vazirizadeh A, Pourahmad J. Selective Toxicity of Cistanche tubulosa Root Extract on Cancerous Skin Mitochondria isolated from animal Model of Melanoma. Cutan Ocul Toxicol 2022;:1-10. [PMID: 35796072 DOI: 10.1080/15569527.2022.2096628] [Reference Citation Analysis]
4 Wang J, Wu H, Zhao Q, Zou Y, Ding D, Yin H, Xu H. Aggregation-Induced Emission Photosensitizer Synergizes Photodynamic Therapy and the Inhibition of the NF-κB Signaling Pathway to Overcome Hypoxia in Breast Cancer. ACS Appl Mater Interfaces 2022. [PMID: 35729075 DOI: 10.1021/acsami.2c06063] [Reference Citation Analysis]
5 Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N. Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. J Med Chem 2022;65:3404-19. [PMID: 35167303 DOI: 10.1021/acs.jmedchem.1c01934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 de Groot E, Varghese S, Tan L, Knighton B, Sobieski M, Nguyen N, Park YS, Powell R, Lorenzi PL, Zheng B, Stephan C, Gopal YNV. Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas. Cancer Metab 2022;10:6. [PMID: 35193687 DOI: 10.1186/s40170-022-00281-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lemberg KM, Gori SS, Tsukamoto T, Rais R, Slusher BS. Clinical development of metabolic inhibitors for oncology. J Clin Invest 2022;132:e148550. [PMID: 34981784 DOI: 10.1172/JCI148550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Saberian C, Sperduto P, Davies MA. Targeted therapy strategies for melanoma brain metastasis. Neurooncol Adv 2021;3:v75-85. [PMID: 34859235 DOI: 10.1093/noajnl/vdab131] [Reference Citation Analysis]
9 Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov 2021. [PMID: 34862480 DOI: 10.1038/s41573-021-00339-6] [Cited by in F6Publishing: 43] [Reference Citation Analysis]
10 Alkaraki A, McArthur GA, Sheppard KE, Smith LK. Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies. Cancers (Basel) 2021;13:5810. [PMID: 34830962 DOI: 10.3390/cancers13225810] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Chen D, Barsoumian HB, Fischer G, Yang L, Verma V, Younes AI, Hu Y, Masropour F, Klein K, Vellano C, Marszalek J, Davies M, Cortez MA, Welsh J. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer 2020;8:e000289. [PMID: 32581056 DOI: 10.1136/jitc-2019-000289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
12 Vachtenheim J, Ondrušová L. Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas. Life (Basel) 2021;11:424. [PMID: 34063141 DOI: 10.3390/life11050424] [Reference Citation Analysis]
13 Zhang X, Shetty M, Clemente V, Linder S, Bazzaro M. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries. Int J Mol Sci 2021;22:4750. [PMID: 33947138 DOI: 10.3390/ijms22094750] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kosaisawe N, Sparta B, Pargett M, Teragawa CK, Albeck JG. Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cells. Cell Metab 2021;33:649-665.e8. [PMID: 33561427 DOI: 10.1016/j.cmet.2021.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Fischer GM, Guerrieri RA, Hu Q, Joon AY, Kumar S, Haydu LE, McQuade JL, Vashisht Gopal YN, Knighton B, Deng W, Hudgens CW, Lazar AJ, Tetzlaff MT, Davies MA. Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. Neurooncol Adv 2021;3:vdaa177. [PMID: 33575655 DOI: 10.1093/noajnl/vdaa177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, Luo CK, Knighton B, Tan L, Lorenzi PL, Mackinnon AL, McQuade JL, Hailemichael Y, Roszik J, Peng W, Vashisht Gopal YN. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. Mol Cancer Ther 2021;20:500-11. [PMID: 33361272 DOI: 10.1158/1535-7163.MCT-20-0430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
17 Fattore L, Mancini R, Ciliberto G. Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma. Cancers (Basel) 2020;12:E3368. [PMID: 33202944 DOI: 10.3390/cancers12113368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Klein K, He K, Younes AI, Barsoumian HB, Chen D, Ozgen T, Mosaffa S, Patel RR, Gu M, Novaes J, Narayanan A, Cortez MA, Welsh JW. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol 2020;11:573326. [PMID: 33178201 DOI: 10.3389/fimmu.2020.573326] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
19 Aminzadeh-Gohari S, Weber DD, Catalano L, Feichtinger RG, Kofler B, Lang R. Targeting Mitochondria in Melanoma. Biomolecules 2020;10:E1395. [PMID: 33007949 DOI: 10.3390/biom10101395] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
20 Sun X, Zhang N, Yin C, Zhu B, Li X. Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. Front Oncol 2020;10:951. [PMID: 32714859 DOI: 10.3389/fonc.2020.00951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
21 Rytelewski M, Harutyunyan K, Baran N, Mallampati S, Zal MA, Cavazos A, Butler JM, Konoplev S, El Khatib M, Plunkett S, Marszalek JR, Andreeff M, Zal T, Konopleva M. Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model. Front Oncol 2020;10:991. [PMID: 32695673 DOI: 10.3389/fonc.2020.00991] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lee SH, Griffiths JR. How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH. Cancers (Basel) 2020;12:E1616. [PMID: 32570870 DOI: 10.3390/cancers12061616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
23 Teh JLF, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso J, Aplin AE. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Mol Cancer Ther 2020;19:1719-26. [PMID: 32430489 DOI: 10.1158/1535-7163.MCT-19-1016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]